Cuprina jumps after Nasdaq compliance update, but risks remain
CUPR soared 74% to $4.20 after Cuprina said Nasdaq confirmed it had regained compliance with minimum bid price rules, removing immediate delisting risk following a 1-for-8 share consolidation; Friday’s rally reflects relief over trading continuity, but with 2025 revenue at just US$38,789 and net loss at US$3.63 million, investors now await proof of commercial traction in chronic wound care markets.